Please assess the completion status of the following clinical trial:

Trial Title: Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients 18 to 80 years of age with Primary hypercholesterolemia or mixed dyslipidemia~* Patients will be eligible for the study if their LDL-C values are within protocol specified range and meet other entry criteria~Exclusion Criteria:~* Patient whose LDL-C values are not within protocol specified range

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: OTHER): One tablet of ER niacin/ laropiprant (1g) + one tablet of the run-in statin dose, titrating up to ER niacin/laropiprant (2g) at Week 4 for an additional 8 weeks, with no adjustments to the run-in statin dose.
- 2 (Type: ACTIVE_COMPARATOR): Stable dose of simvastatin or atorvastatin (20mg to 40mg) for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).